Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the national Class 1 innovative drug TQB3909 tablets (BCL-2 inhibitors) independently developed by the Group's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), have submitted a new drug marketing application to the China National Drug Administration Drug Evaluation Center (CDE) and accepted for the treatment of adult chronic lymphocytic leukemia/microlymphocytic lymphoma (CLL/SLL).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.